Free testosterone and cardiometabolic parameters in men: Comparison of algorithms
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Free testosterone and cardiometabolic parameters in men : Comparison of algorithms. / Holmboe, Stine A.; Jasuja, Ravi; Lawney, Brian; Priskorn, Lærke; Joergensen, Niels; Linneberg, Allan; Jensen, Tina Kold; Skakkebæk, Niels Erik; Juul, Anders; Andersson, Anna Maria.
In: Endocrine Connections, Vol. 10, No. 2, 2021, p. 220-229.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Free testosterone and cardiometabolic parameters in men
T2 - Comparison of algorithms
AU - Holmboe, Stine A.
AU - Jasuja, Ravi
AU - Lawney, Brian
AU - Priskorn, Lærke
AU - Joergensen, Niels
AU - Linneberg, Allan
AU - Jensen, Tina Kold
AU - Skakkebæk, Niels Erik
AU - Juul, Anders
AU - Andersson, Anna Maria
PY - 2021
Y1 - 2021
N2 - Objective: Calculating the free testosterone level has gained increasing interest and different indirect algorithms have been suggested. The objective was to compare free androgen index (FAI), free testosterone estimated using the linear binding model (Vermeulen: cFTV) and the binding framework accounting for allosterically coupled SHBG monomers (Zakharov: cFTZ) in relation to cardiometabolic conditions. Design: A prospective cohort study including 5350 men, aged 30–70 years, participating in population-based surveys (MONICA I–III and Inter99) from 1982 to 2001 and followed until December 2012 with baseline and follow-up information on cardiometabolic parameters and vital status. Results: Using age-standardized hormone levels, FAI was higher among men with baseline cardiometabolic conditions, whereas cFTV and cFTZ levels were lower compared to men without these conditions as also seen for total testosterone. Men in highest quartiles of cFTV or cFTZ had lower risk of developing type 2 diabetes (cFTV: HR = 0.74 (0.49–1.10), cFTZ: HR = 0.59 (0.39–0.91)) than men in lowest quartile. In contrast, men with highest levels of FAI had a 74% (1.17–2.59) increased risk of developing type 2 diabetes compared to men in lowest quartile. Conclusion: The association of estimated free testosterone and the studied outcomes differ depending on algorithm used. cFTV and cFTZ showed similar associations to baseline and long-term cardiometabolic parameters. In contrast, an empiric ratio, FAI, showed opposite associations to several of the examined parameters and may reflect limited clinical utility.
AB - Objective: Calculating the free testosterone level has gained increasing interest and different indirect algorithms have been suggested. The objective was to compare free androgen index (FAI), free testosterone estimated using the linear binding model (Vermeulen: cFTV) and the binding framework accounting for allosterically coupled SHBG monomers (Zakharov: cFTZ) in relation to cardiometabolic conditions. Design: A prospective cohort study including 5350 men, aged 30–70 years, participating in population-based surveys (MONICA I–III and Inter99) from 1982 to 2001 and followed until December 2012 with baseline and follow-up information on cardiometabolic parameters and vital status. Results: Using age-standardized hormone levels, FAI was higher among men with baseline cardiometabolic conditions, whereas cFTV and cFTZ levels were lower compared to men without these conditions as also seen for total testosterone. Men in highest quartiles of cFTV or cFTZ had lower risk of developing type 2 diabetes (cFTV: HR = 0.74 (0.49–1.10), cFTZ: HR = 0.59 (0.39–0.91)) than men in lowest quartile. In contrast, men with highest levels of FAI had a 74% (1.17–2.59) increased risk of developing type 2 diabetes compared to men in lowest quartile. Conclusion: The association of estimated free testosterone and the studied outcomes differ depending on algorithm used. cFTV and cFTZ showed similar associations to baseline and long-term cardiometabolic parameters. In contrast, an empiric ratio, FAI, showed opposite associations to several of the examined parameters and may reflect limited clinical utility.
KW - Follow-up study
KW - Free testosterone
KW - Metabolic syndrome
KW - Total testosterone
U2 - 10.1530/EC-20-0552
DO - 10.1530/EC-20-0552
M3 - Journal article
C2 - 33544092
AN - SCOPUS:85103013894
VL - 10
SP - 220
EP - 229
JO - Endocrine Connections
JF - Endocrine Connections
SN - 2049-3614
IS - 2
ER -
ID: 259622958